Panacea Biotec

how big is Panacea Biotec?

As of Jun 06, Panacea Biotec Ltd has a market capitalization of 2,740.36 Cr, classifying it as a Small Cap company, with net sales of 559.09 Cr and a net profit of -8.54 Cr for the latest four quarters. The company has shareholder's funds of 842.05 Cr and total assets of 1,240.67 Cr as of the latest annual period ending in Mar 24.

Market Cap: As of Jun 06, Panacea Biotec Ltd has a market capitalization of 2,740.36 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Panacea Biotec reported net sales of 559.09 Cr and a net profit of -8.54 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar 24. The company has shareholder's funds amounting to 842.05 Cr and total assets of 1,240.67 Cr.

What does Panacea Biotec do?

Panacea Biotec Ltd is a leading Indian research-based health management company in the Pharmaceuticals & Biotechnology sector, with a market cap of Rs 2,750 Cr. As of March 2025, it reported net sales of 133 Cr and a net loss of 2 Cr.

Overview:<BR>Panacea Biotec Ltd is India's leading research-based health management company operating in the Pharmaceuticals & Biotechnology industry within the small-cap market segment.<BR><BR>History:<BR>The company was incorporated on February 2, 1984, originally under the name Panacea Drug (P) Ltd. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 133 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 2,750 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.11 <BR>Return on Equity: -5.33% <BR>Price to Book: 3.46<BR><BR>Contact Details:<BR>Address: Ambala-Chandigarh Highway, Lalru Punjab: 140501 <BR>Phone: 91-1762-505900 <BR>Email: companysec@panaceabiotec.com <BR>Website: http://www.panaceabiotec.com

Who are in the management team of Panacea Biotec?

As of March 2022, the management team of Panacea Biotec includes Chairman Rajesh Jain, Joint Managing Director Sandeep Jain, Group CFO Vinod Goel, and several independent directors, totaling a mix of executive and non-executive members.

As of March 2022, the management team of Panacea Biotec includes the following individuals:<BR><BR>1. Soshil Kumar Jain - Chairman & Executive Director<BR>2. Rajesh Jain - Chairman & Managing Director<BR>3. Sandeep Jain - Joint Managing Director<BR>4. R L Narasimhan - Non-Executive & Independent Director<BR>5. N N Khamitkar - Non-Executive & Independent Director<BR>6. K M Lal - Non-Executive & Independent Director<BR>7. Vinod Goel - Group CFO & Company Secretary<BR>8. Manjula Upadhyay - Non-Executive & Independent Director<BR>9. Mukul Gupta - Non-Executive & Independent Director<BR>10. Ankesh Jain - Whole-time Director<BR>11. Bhupinder Singh - Non-Executive & Independent Director<BR>12. Narotam Kumar Juneja - Director<BR><BR>This team comprises a mix of executive and non-executive members, with various roles contributing to the company's governance and management.

Has Panacea Biotec declared dividend?

Yes, Panacea Biotec Ltd has declared a 75% dividend, amounting to ₹0.75 per share, with an ex-date of September 19, 2011. However, the dividend yield is 0%, as it has not contributed to returns in recent periods, despite significant price returns.

Panacea Biotec Ltd has declared a 75% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 0.75<BR>- Ex-date: 19 Sep 11<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 2.49%, the dividend return was 0%, resulting in a total return of 2.49%.<BR><BR>For the 1-year period, the price return was 253.27%, the dividend return was 0%, leading to a total return of 253.27%.<BR><BR>Over the 2-year period, the price return was 272.84%, with a dividend return of 0%, culminating in a total return of 272.84%.<BR><BR>In the 3-year period, the price return was 203.06%, the dividend return was 0%, resulting in a total return of 203.06%.<BR><BR>For the 4-year period, the price return was 15.05%, with a dividend return of 0%, leading to a total return of 15.05%.<BR><BR>In the 5-year period, the price return was 177.17%, the dividend return was 0%, culminating in a total return of 177.17%.<BR><BR>Overall, while Panacea Biotec has declared a dividend, the dividend yield is 0%, indicating that the dividend has not contributed to returns in recent periods. The company has experienced significant price returns over various periods, suggesting strong performance in its stock value.

Who are the peers of the Panacea Biotec?

Panacea Biotec's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, IOL Chemicals, Novartis India, and Senores Pharma. Panacea Biotec has the highest 1-year return at 269.46%, while Orchid Pharma has the lowest at -31.48%.

Peers: The peers of Panacea Biotec are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, IOL Chemicals, Novartis India, and Senores Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at IOL Chemicals and Novartis India. Below Average management risk is noted for Orchid Pharma, Panacea Biotec, and Senores Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Divi's Lab., Torrent Pharma, Orchid Pharma, Panacea Biotec, and Zota Health Care. Average growth is noted for IOL Chemicals and Novartis India, with Excellent growth at Senores Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and IOL Chemicals, while Good capital structure is found at Torrent Pharma and Senores Pharma. Below Average capital structure is observed at Orchid Pharma, Panacea Biotec, and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 269.46%, while the lowest is Orchid Pharma at -31.48%. Panacea Biotec's 1-year return significantly exceeds all its peers. Additionally, Orchid Pharma and Zota Health Care have negative six-month returns.

Is Panacea Biotec overvalued or undervalued?

As of November 13, 2020, Panacea Biotec is considered risky and overvalued with a negative PE ratio of -61.96 and an EV to EBITDA of -103.02, significantly worse than its peers, despite a 252.56% return over the past year.

As of 13 November 2020, the valuation grade for Panacea Biotec has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued, given its negative PE ratio of -61.96 and EV to EBITDA ratio of -103.02, which are starkly contrasting with its peers. The Price to Book Value stands at 3.30, suggesting that the market is pricing the company at a premium despite its financial struggles.<BR><BR>In comparison to its peers, Panacea Biotec's ratios are considerably worse; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight the challenges Panacea Biotec faces in the market. Additionally, while the company has shown impressive returns over the past year at 252.56%, this performance is not enough to justify its current valuation in light of its financial metrics.

Who are the top shareholders of the Panacea Biotec?

The top shareholder of Panacea Biotec is Dr. Rajesh Jain, who holds 49.33% of the shares. Individual investors own 18.45%, while 14 foreign institutional investors hold a combined 1.16%, with no mutual funds currently invested.

The top shareholders of Panacea Biotec include the promoters, with Dr. Rajesh Jain holding the highest stake at 49.33%. There are no pledged promoter holdings, and individual investors collectively hold 18.45% of the shares. Additionally, 14 foreign institutional investors (FIIs) hold a combined 1.16% of the company. There are no mutual funds currently holding shares in Panacea Biotec.

When is the next results date for Panacea Biotec?

The next results date for Panacea Biotec is 14 August 2025.

The next results date for Panacea Biotec is scheduled for 14 August 2025.

How has been the historical performance of Panacea Biotec?

Panacea Biotec's historical performance shows fluctuating financial metrics, with stable net sales but increasing operating losses, resulting in a decline in profit before and after tax. Despite a slight increase in total assets and improved cash flow from investing activities, the company faces challenges in profitability.

Answer:<BR>The historical performance of Panacea Biotec shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Panacea Biotec's net sales have remained relatively stable, with a slight decrease from 559.17 crore in March 2024 to 559.09 crore in March 2025, following a notable drop from 661.23 crore in March 2022. The total operating income mirrored this trend, peaking at 661.23 crore in March 2022 before declining to 559.09 crore in March 2025. The company's total expenditure, excluding depreciation, increased from 579.23 crore in March 2024 to 585.00 crore in March 2025, contributing to an operating loss of 25.91 crore in March 2025, compared to a loss of 20.06 crore in March 2024. Profit before tax also saw a decline, moving from a profit of 1.48 crore in March 2024 to a loss of 7.95 crore in March 2025. Consequently, the profit after tax worsened from a loss of 1.50 crore in March 2024 to a loss of 8.72 crore in March 2025. The company's total assets increased slightly from 1,240.82 crore in March 2024 to 1,289.75 crore in March 2025, while total liabilities also rose from 1,240.82 crore to 1,289.75 crore during the same period. Cash flow from operating activities remained negative at -27.00 crore in March 2025, although cash flow from investing activities improved significantly to 64.00 crore. Overall, the financial performance of Panacea Biotec reflects challenges in profitability despite stable revenue figures.

Is Panacea Biotec technically bullish or bearish?

As of December 1, 2025, Panacea Biotec's technical trend is bearish, supported by bearish signals from the weekly MACD and KST, daily moving averages, and a lack of strong indicators from the RSI and Dow Theory, despite mildly bullish monthly Bollinger Bands.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Panacea Biotec is bearish, with a moderate strength indicated by the weekly MACD and KST both showing bearish signals. The daily moving averages also confirm a bearish outlook. Although the monthly Bollinger Bands are mildly bullish, they do not outweigh the bearish indicators present in the weekly timeframe. Overall, the lack of significant signals from the RSI and Dow Theory further supports a bearish sentiment.

Are Panacea Biotec Ltd latest results good or bad?

Panacea Biotec Ltd's latest results show mixed performance: while revenue grew by 1.04% and operating margins improved, net profit declined by 11.95%, indicating ongoing profitability challenges. Overall, the results are more concerning than favorable due to stock underperformance and earnings volatility.

The latest results for Panacea Biotec Ltd present a mixed picture. On one hand, the company reported a modest revenue growth of 1.04% year-on-year, with net sales reaching ₹165.19 crores. Additionally, the operating margin improved to 7.11%, which is a positive sign compared to the previous year's margin of 4.87%. <BR><BR>However, the net profit of ₹3.98 crores reflects a significant decline of 11.95% year-on-year, indicating ongoing challenges in profitability. The volatility in earnings is concerning, as the company swung from a loss of ₹13.92 crores in the previous quarter to a profit this quarter, highlighting instability in its operational performance.<BR><BR>Furthermore, the stock has been underperforming, trading significantly below its 52-week high and showing negative returns over various timeframes. The overall assessment suggests that while there are some improvements in revenue and margins, the persistent issues with profitability and stock performance indicate that the results are more concerning than favorable.

Should I buy, sell or hold Panacea Biotec Ltd?

Which are the latest news on Panacea Biotec?

Why is Panacea Biotec Ltd falling/rising?

As of 17-Mar, Panacea Biotec Ltd's stock price is slightly rising at 317.45, but it has significantly underperformed over the past year with a decline of 17.81%. The stock shows weak fundamentals and bearish trends, indicating potential continued volatility and declines.

As of 17-Mar, Panacea Biotec Ltd's stock price is experiencing a slight rise, currently at 317.45, with a change of 0.15 (0.05%) upward. This increase comes after a trend reversal, as the stock has gained after four consecutive days of decline. However, despite this minor uptick, the stock has shown significant underperformance over various periods, including a 1-year decline of 17.81%, while the broader market (BSE500) has generated positive returns of 6.18% in the same timeframe.<BR><BR>The stock is currently trading 3.61% away from its 52-week low, indicating that it is close to a significant low point. Additionally, Panacea Biotec is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 29.57% against the 5-day average, reflecting reduced interest from investors.<BR><BR>The company's long-term fundamentals are weak, highlighted by an average Return on Equity (ROE) of 0% and a concerning operating profit growth rate of -250.53% over the last five years. The company's ability to service its debt is also weak, as indicated by a poor EBIT to Interest ratio of -8.48. These factors contribute to the perception of the stock as a strong sell, further exacerbated by the fact that domestic mutual funds hold no stake in the company, which may indicate a lack of confidence in its prospects.<BR><BR>In summary, while there is a slight rise in the stock price today, the overall trend and fundamental indicators suggest that Panacea Biotec Ltd is facing significant challenges that could lead to continued volatility and potential declines in the future.

Why is Panacea Biotec Ltd falling/rising?

As of 18-Mar, Panacea Biotec Ltd's stock price is rising to Rs 341.35, reflecting a 7.53% increase. However, despite this short-term gain, the stock has a year-to-date decline of 9.28% and faces long-term challenges, including weak fundamentals and declining investor participation.

As of 18-Mar, Panacea Biotec Ltd's stock price is rising, currently at Rs 341.35, reflecting a change of Rs 23.9 or 7.53% increase. This upward movement is notable as the stock has outperformed its sector by 7.26% today and has experienced consecutive gains over the last two days, accumulating a total return of 7.58% during this period. Additionally, the stock reached an intraday high of Rs 342.65, indicating strong trading activity.<BR><BR>However, despite the recent price increase, the stock has shown a negative performance over longer periods, with a year-to-date decline of 9.28% and a one-year drop of 17.07%. The stock's performance has also been weak compared to the broader market, as it has underperformed the BSE500 index, which generated positive returns of 5.49% over the last year.<BR><BR>Investor participation appears to be declining, with delivery volume falling by 52.43% against the five-day average, suggesting that while the stock is currently rising, there are underlying concerns about its long-term fundamentals. The company has a weak return on equity of 0% and has reported a significant decline in operating profit over the last five years. Furthermore, the stock is considered risky due to negative EBITDA and poor debt servicing capabilities.<BR><BR>In summary, while Panacea Biotec Ltd is experiencing a rise in stock price in the short term, this is juxtaposed with significant long-term challenges that may affect investor confidence moving forward.

Why is Panacea Biotec Ltd falling/rising?

As of 19-Mar, Panacea Biotec Ltd's stock price is at 333.00, down 2.45%, with a significant decline in performance over the past week and month. Weak fundamentals, including a 0% ROE and poor debt servicing ability, contribute to a lack of investor confidence and the stock's overall decline.

As of 19-Mar, Panacea Biotec Ltd's stock price is falling, currently at 333.00, reflecting a change of -8.35 (-2.45%). The stock has underperformed the sector by 0.3% today and opened with a loss of 2.11%. It reached an intraday low of Rs 325.7, which is a decline of 4.58%. The stock's performance over the past week shows a decrease of 2.23%, while it has also fallen by 4.09% over the past month.<BR><BR>The stock's trend indicates a reversal, having fallen after two consecutive days of gains. Additionally, the overall performance of the Pharmaceuticals & Drugs sector has declined by 2.13%. Investor participation has also decreased, with delivery volume falling by 14.54% compared to the five-day average. <BR><BR>From a longer-term perspective, Panacea Biotec Ltd has shown weak fundamental strength, with an average Return on Equity (ROE) of 0% and a significant decline in operating profit at an annual rate of -250.53% over the last five years. The company's ability to service its debt is also concerning, as indicated by a poor EBIT to Interest ratio of -8.48. Furthermore, the stock has generated a return of -22.94% over the past year, significantly underperforming the market, which has seen a return of 1.22% in the same period. <BR><BR>These factors collectively contribute to the stock's decline, reflecting a lack of investor confidence and poor financial health.

Why is Panacea Biotec Ltd falling/rising?

As of 20-Mar, Panacea Biotec Ltd's stock price is rising to 330.25, but it has underperformed over the past year with a -26.91% return. Despite today's gains, the stock shows weak long-term fundamentals and mixed signals regarding its trend.

As of 20-Mar, Panacea Biotec Ltd's stock price is rising, currently at 330.25, reflecting a change of 2.15 (0.66%) upward. The stock opened with a significant gain of 6.03% today, reaching an intraday high of Rs 347.9. However, despite this short-term rise, the stock has been underperforming in the broader market context, as it has generated negative returns of -26.91% over the past year, compared to a market return of 0.76% during the same period.<BR><BR>The stock's performance today has been characterized by high volatility, with an intraday volatility of 5.04%. While it is trading above its 5-day moving averages, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, indicating mixed signals regarding its longer-term trend. Additionally, the stock has underperformed its sector by -1.04% today, and there has been a notable decline in investor participation, with delivery volume falling by -68.75% against the 5-day average.<BR><BR>Despite the current rise in price, the overall fundamentals of Panacea Biotec Ltd suggest a weak long-term outlook, with an average Return on Equity (ROE) of 0% and a concerning EBIT to Interest ratio of -8.48. The company's operating profit has also declined significantly, indicating challenges in sustaining growth. Therefore, while the stock may be experiencing a temporary rise, the underlying factors suggest a precarious position for future performance.

Why is Panacea Biotec Ltd falling/rising?

As of 23-Mar, Panacea Biotec Ltd's stock price is at 319.35, down 2.65% and on a downward trend for three consecutive days. The stock has significantly underperformed with a year-to-date drop of 15.12% and concerns over weak fundamentals and market sentiment.

As of 23-Mar, Panacea Biotec Ltd's stock price is falling, currently at 319.35, reflecting a decrease of 8.7 (-2.65%). The stock has been on a downward trend, having lost value for the last three consecutive days, resulting in a total decline of 6.44% during this period. Additionally, the stock opened with a loss of 2.19% today and reached an intraday low of Rs 315, which is 4.18% away from its 52-week low of Rs 306.<BR><BR>The stock's performance over various periods indicates a significant decline, with a year-to-date drop of 15.12% and a one-year decrease of 28.24%, which is notably worse than the broader market's decline of 5.47% during the same timeframe. Furthermore, Panacea Biotec is trading below its moving averages across multiple timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend.<BR><BR>The company's fundamentals also present concerns, with a weak long-term growth outlook and an average Return on Equity (ROE) of 0%. The operating profit has decreased at an alarming rate of -250.53% over the last five years, and the company's ability to service its debt is compromised, as evidenced by a poor EBIT to Interest ratio of -8.48. Additionally, domestic mutual funds hold no stake in the company, which may reflect a lack of confidence in its valuation or business prospects.<BR><BR>Overall, the combination of poor stock performance, weak fundamentals, and negative market sentiment contributes to the ongoing decline in Panacea Biotec Ltd's stock price.

Why is Panacea Biotec Ltd falling/rising?

As of 24-Mar, Panacea Biotec Ltd's stock price is rising to Rs 327.70, driven by positive short-term performance and increased investor participation, despite longer-term declines of 12.90% year-to-date and 26.19% over the past year.

As of 24-Mar, Panacea Biotec Ltd's stock price is rising, currently at Rs 327.70, reflecting a change of Rs 7.25 or 2.26%. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.14% today, indicating a positive trend relative to its peers. Additionally, it opened with a significant gain of 3.43% and reached an intraday high of Rs 334.3, which is a 4.32% increase. <BR><BR>Moreover, there has been a notable rise in investor participation, with a delivery volume of 1.49 lacs on 23 March, which is up by 135.75% compared to the 5-day average. This suggests increased interest and confidence among investors, contributing to the stock's upward movement. <BR><BR>Furthermore, the stock has experienced a trend reversal, gaining after three consecutive days of decline, which may indicate a shift in market sentiment. However, it is important to note that despite this short-term rise, the stock has underperformed over longer periods, with a year-to-date decline of 12.90% and a one-year drop of 26.19%. <BR><BR>In summary, the current rise in Panacea Biotec Ltd's stock price is primarily driven by positive short-term performance indicators and increased investor activity, despite the backdrop of longer-term challenges.

Why is Panacea Biotec Ltd falling/rising?

As of 25-Mar, Panacea Biotec Ltd's stock price is declining, currently at Rs 324.90, with a one-year return of -24.97%. Weak financial fundamentals, significant market underperformance, and negative investor sentiment contribute to this decline.

As of 25-Mar, Panacea Biotec Ltd's stock price is falling, currently at Rs 324.90, reflecting a decrease of Rs 3.7 or 1.13%. The stock has underperformed the market significantly, with a one-year return of -24.97%, compared to the broader market's decline of only -3.52%. This stark contrast indicates that the stock has not only failed to keep pace with market trends but has also experienced a much steeper decline.<BR><BR>The company's long-term fundamentals are weak, highlighted by an average Return on Equity (ROE) of 0% and a troubling operating profit growth rate of -250.53% over the last five years. Additionally, the company's ability to service its debt is concerning, as evidenced by a poor EBIT to Interest ratio of -8.48. These factors contribute to a perception of risk among investors.<BR><BR>Moreover, the stock's performance today shows it is trading below all key moving averages, which typically signals bearish sentiment. Despite a notable increase in delivery volume, which rose by 233.72% against the five-day average, the overall market sentiment remains negative. The stock's liquidity is adequate, but the lack of domestic mutual fund investment—holding only 0%—suggests that institutional investors may lack confidence in the company's prospects.<BR><BR>In summary, the combination of weak financial fundamentals, significant underperformance relative to the market, and negative investor sentiment are key reasons for the decline in Panacea Biotec Ltd's stock price.